SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DaveAu who wrote (4083)4/13/2000 7:25:00 AM
From: Mark Bartlett  Read Replies (2) of 14101
 
Bluejay,

There are a couple of things I want to get clarified too and your query is one of them. I believe I know what they mean, but before I comment, I want to get clarified first.

This study is still double-blinded, so it is impossible to assign SAE events to any one group -- as far as we know they may have all been in the placebo, the WF10 group, or in a weighted or equal combination in both groups. The fact that the trial remains ongoing suggests the SAEs are at least equal to, or less than what one would statistically expect, if no one were getting the drug.

My gut feeling is the researchers are seeing some positive things happening in some of the study participants ( either stabilization or improvement) and deterioration in others. If the "deterioration" group are following a pattern typical for late-stage AIDS patients, then by logical reasoning one could imply that those who are improving, are improving because of WF10.

MB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News